In vitro Antimicrobial Activity of Acne Drugs Against Skin-Associated Bacteria

Mark A. T. Blaskovich, Alysha G. Elliott, Angela M. Kavanagh, Soumya Ramu & Matthew A. Cooper

Acne is a common skin affliction that involves excess sebum production and modified lipid composition, duct blockage, colonization by bacteria, and inflammation. Acne drugs target one or more of these steps, with antibiotics commonly used to treat the microbial infection for moderate to severe cases. Whilst a number of other acne therapies are purported to possess antimicrobial activity, this has been poorly documented in many cases. We conducted a comparative analysis of the activity of common topical acne drugs against the principal etiological agent associated with acne: the aerotolerant anaerobic Gram-positive organism Propionibacterium acnes (recently renamed as Cutibacterium acnes). We also assessed their impact on other bacteria that could also be affected by topical treatments, including both antibiotic-sensitive and antibiotic-resistant strains, using broth microdilution assay conditions. Drugs designated specifically as antibiotics had the greatest potency, but lost activity against resistant strains. The non-antibiotic acne agents did possess widespread antimicrobial activity, including against resistant strains, but at substantially higher concentrations. Hence, the antimicrobial activity of non-antibiotic acne agents may provide protection against a background of increased drug-resistant bacteria.

Acne vulgaris is a common skin disease that affects almost all teenagers and many adults to a degree. It is estimated as the eighth most prevalent global disease, with 650 million people reported to have had acne in 2010. The development of acne proceeds in four stages, starting with excess sebum production and modified lipid composition in the sebaceous gland at the base of hair follicles, which is followed by blocking of the skin pore, then colonization by Propionibacterium acnes (recently renamed as Cutibacterium acnes, but with the original designation still favored in the dermatological community), which induces inflammation and pustule formation. Treatment options include skin cleansing to remove excess oil and unblock pores, skin abrasives (including chemical peeling agents such as benzoyl peroxide, azelaic acid, and salicylic acid) to increase cell turnover and help remove lesions, hormones or retinoid treatment to reduce sebum production, and antibiotics to reduce the bacterial infection.

Antibiotics prescribed for acne can be topical or systemic. For systemic treatment, usually reserved for more severe acne, the oral tetracyclines (tetracycline, oxytetracycline, doxycycline, minocycline or lymecycline) are most commonly used. Oral clindamycin is effective but has adverse effects, while macrolides (erythromycin and azithromycin), trimethoprim and the β-lactams ampicillin/amoxicillin/oxacillin are discouraged due to concerns over growing resistance. The use of systemic antibiotics, other than the tetracyclines and macrolides, is not recommended due to limited data supporting their use to treat acne. Topical antibiotic options include tetracycline, clindamycin, and erythromycin, sometimes in combination with benzoyl peroxide and zinc acetate. Dapsone (diaminodiphenyl sulfone) is an anti-inflammatory agent with antimicrobial properties, has also been used. However, a number of other topical agents are proposed to act via multiple mechanisms, with the exfoliants benzoyl peroxide, azelaic acid, and salicylic acid commonly ascribed to also have antimicrobial activity.

The growing global crisis of antibiotic resistance is also reflected in antimicrobial acne therapy. Resistant strains of P. acnes have been reported in many countries (with resistance especially noted to topical erythromycin and clindamycin), and topical antibiotic use is associated with resistance in other commensal bacteria, such as Staphylococcus aureus. The American Academy of Dermatology recommends that systemic antibiotic use should...
be limited to the shortest possible duration with re-evaluation at 3–4 months to minimize the development of bacterial resistance, and co-application of benzoyl peroxide (BP) to help reduce the development of resistance. Topical therapy is strongly suggested to follow the discontinuation of systemic antibiotics as a maintenance regimen. The European Evidence-Based Guideline for the Treatment of Acne has similar recommendations.

The rise in antimicrobial resistance is accompanied by an increasing awareness of the role of the human microbiome in the ability of pathogenic species to establish an infection. Several recent genomic studies have specifically examined the human skin microbiome and even the subpopulation of *P. acnes* in the human skin microbiome. These studies identify abundant populations of *P. acnes* and *Staphylococcus* spp. (especially *S. epidermidis*, but also *S. aureus* and *S. hominis*, and lower levels of *S. warneri*, *S. saprophyticus*, *S. lugdunensis*, *S. haemolyticus* and *S. capitis*). High levels of Corynebacterium, *Streptococcus mitis* and the fungus *Malassezia globosa* have also been identified, with community composition varying depending on the skin region and skin type (sebaceous, dry skin or wet skin). Altering the skin microbiome with topical antibiotic treatment can have significant effects on the cutaneous host defense, and some skin bacteria (such as *Micrococcus luteus*) have been found to enhance *S. aureus* pathogenesis. A new anti-acne tetracycline, sarecycline, has been designed as the first narrow-spectrum tetracycline-class antibiotic being developed for acne treatment, reducing collateral damage on the microbiome (though in this case used systemically, not topically).

It is important to know the relative effects of antimicrobial agents on human microbiota in order to understand their potential to foster resistance and alter the microbiome composition. To date, there has not been a comparative assessment of the antimicrobial activity of commonly used antibiotics and topical acne agents against a set of representative commensal skin bacteria, including those not directly associated with acne. We now report such a study against standardized accessible organisms from reference collections, testing both specific antibiotics used to treat acne (tetracycline, erythromycin, clindamycin, oxacillin, dapsone, along with control antibiotics vancomycin/colistin) and other acne agents reported to have antimicrobial activity (salicylic acid, azelaic acid, benzoyl peroxide) (see Fig. 1). These are assessed against both sensitive and resistant bacterial strains, under anaerobic and aerobic conditions. In addition to some of the most common strains identified by microbiome studies, we also include several additional pathogenic bacteria that can be found on the skin and/or involved in skin infections, such as *Streptococci* (*S. pyogenes* and, less commonly *S. pneumoniae*), *Bacilli* (*B. subtilis*, *B. cereus* and *B. megaterium*), *Enterococci* (*E. faecium* and *E. faecalis*), *Micrococcus* (*M. luteus* and *Kocuria rosea*) and the Gram-negative bacteria *Escherichia coli* and *Acinetobacter johnsonii*.

**Results and Discussion**

The antimicrobial activity of the antibiotics and anti-acne agents, tested under standard broth microdilution (BMD) conditions, are summarized in Tables 1–3. The topical acne therapeutics originally developed as specific antimicrobial agents (tetracycline, erythromycin, oxacillin, and clindamycin) generally showed potent activity under both anaerobic and aerobic conditions against a range of bacteria, though erythromycin, oxacillin and
clindamycin lost substantial activity against resistant bacteria, such as MRSA (methicillin-resistant *S. aureus*) and MDR (multidrug-resistant) *S. pneumoniae*. Dapsone, an aniline sulfone first made in 1908 but discovered as an antimicrobial agent in 1937, was generally less effective than the other antibiotics but had widely varying activity

**Table 1.** Minimum Inhibitory Concentrations measured under anaerobic conditions, µg/mL. [n = 4, duplicate results from 2 independent assays.]

| Anti-acne agent Bacteria | antibiotics | non-antibiotics |
|--------------------------|-------------|----------------|
|                          | Vancomycin | Tetracycline | Erythromycin | Oxacillin | Clindamycin | Dapsone | Salicylic acid | Azelaic acid | Benzoyl peroxide 75% |
| *P. acnes* ATCC 6919     | 0.25–1     | 0.125–1     | 0.25         | 0.25–1  | 0.125      | 4100    | 4000–8000    | 4000–8000    | 1024–>2048    |
| *A. acidropropionici* ATCC 25562 | 0.125     | 0.5         | 0.25–4     | 0.25–1  | 0.03–0.125 | 1025–>4100 | 500–8000    | 4000–16000   | 1024–>2048    |
| *C. granulosum* ATCC 25564 | 0.25     | 0.25        | 0.125–2    | 0.25–4  | 0.03–0.25  | 512–>4100 | 2000–8000   | 4000–8000    | 1024–>2048    |
| *S. aureus*, MRSA ATCC 43300 | 1        | 0.25        | >32        | 8–64    | >32        | >4100   | 4000–8000   | 2000–8000    | 2048–>2048    |

**Table 2.** Minimum Inhibitory Concentrations against Gram-Positive bacteria measured under aerobic conditions, µg/mL. [n = 4, duplicate results from 2 independent assays; MIC variations indicated. Bacterial species in bold are resistant.]

| Anti-acne agent Bacteria | antibiotics | non-antibiotics |
|--------------------------|-------------|----------------|
|                          | Vancomycin | Tetracycline | Erythromycin | Oxacillin | Clindamycin | Dapsone | Salicylic acid | Azelaic acid | Benzoyl peroxide 75% |
| *S. aureus*, MSSA ATCC 25923 | 1        | 0.25–0.5     | 1           | 0.125–0.25 | 0.125      | 256     | 32000        | 16000        | >2048–2048    |
| *S. aureus*, MSSA ATCC 29213 | 1        | 0.5         | 1           | 0.25–0.125 | 0.06–0.03  | 512–1024 | 64000        | 16000        | 2048          |
| *S. aureus*, MRSA ATCC 43300 | 1        | 0.25        | >32         | 16       | >32        | 128–256 | 32000        | 16000        | 2048          |
| *S. aureus*, MRSA ATCC 33591 | 1        | >32         | >32         | >64      | >32        | >4100   | 64000        | 16000        | ≥2048         |
| *S. aureus*, GISA NRS1     | 4        | 32          | >32         | >64      | >32        | 256–512 | 32000        | 8000         | 2048          |
| *S. aureus*, VRSA VRS1     | >64       | 1           | >32         | >64      | >32        | 512–025 | 32000        | 2000–16000   | 2048          |
| *S. capsitis* ATCC 27840   | 1–2       | 32          | 0.5         | 0.06–0.125 | 0.06–0.125 | 128    | 4000         | 8000–6000    | 2048          |
| *S. epidermidis* ATCC 12228 | 1        | ≥32         | 0.5         | 0.125    | 0.06      | >4100   | 8000         | 8000         | 2048          |
| *S. epidermidis* ATCC 14990 | 1/2     | 16–32       | 0.25–0.5   | 0.03–0.06  | 0.03     | 128     | 2000–4000   | 16000        | 2048          |
| *S. epidermidis*, VISE NRS60 | 4      | 32          | >32         | 8        | ≤0.015    | 256–1025 | 8000–16000  | 8000–16000   | 2048          |
| *S. warneri* ATCC 27836    | 1        | 0.5         | 0.5         | 0.03     | 4         | 32000   | 16000        | 2048          |
| **Other organisms**        |            |              |              |          |           |         |              |              |               |
| *B. cereus* ATCC 11778     | 1        | ≤0.015      | 0.25        | >64      | 0.5       | 256     | 32000        | 8000–16000   | 2048          |
| *B. megaterium* ATCC 13632 | 0.125  | 0.5         | 0.25–0.5   | 32       | 64        | 16000–32000 | 8000–16000   | 2048          |
| *B. subtilis* ATCC 6633    | 0.06–0.125 | 0.06–0.125 | 0.125     | 0.25     | 1         | 4–8     | 32000        | 8000–16000   | 2048          |
| *E. faecium* ATCC 35667    | 0.5–1    | 0.5–0.25    | 2–4        | 16       | ≤0.015    | >4100   | 32000        | 16000        | ≥2048         |
| *E. faecalis* ATCC 29212   | 2        | 32          | 2–4        | 8        | 16        | 16      | 32000        | 16000        | 1024–2048     |
| *K. rosea* ATCC 31251      | 1–2      | 32–16       | 0.25       | 0.06–0.12 | 0.03–0.06 | 128–256 | 2000        | 2000–16000   | 2048          |
| *M. luteus* ATCC 4698      | 0.06–0.25 | 0.06–0.125  | 0.25       | 2–4      | 0.015–0.125 | 256   | 2000–4000   | 4000         | 1024          |
| *S. pneumoniae* ATCC 33400 | 1        | 0.125–0.25  | 0.015–0.5  | 0.25     | 0.06      | 256–512 | 32000        | 8000         | 2048          |
| *S. pneumoniae*, MDR ATCC 700677 | 1 | >32      | >32        | >64      | >32       | >4100   | 32000        | 16000        | 2048          |
| *S. pyogenes* ATCC 14289    | 0.25–0.125 | 0.06       | ≤0.015     | ≤0.03    | ≤0.015    | ≤2      | 1000–2000   | 4000         | 2048          |
that was dependent on the species (ranging from <2 µg/mL for S. pyogenes to >4100 µg/mL against a S. epidermidis strain, with the variable activity potentially partly due to poor solubility when diluting from stock solutions into media at high concentrations). Previous literature reports for both Minimum Inhibitory Concentration (MIC) potency of tetracycline, erythromycin and clindamycin against P. acnes also showed a wide variation among strains, with activity ranges of ≤0.06 to 31, ≤0.25 to >1000, and ≤0.125 to >500 µg/mL respectively for the three antibiotics, with results from the current study generally fitting into these ranges.

In sharp contrast, the 'non-antibiotic' acne agents (salicylic acid, azelaic acid and benzoyl peroxide) that are believed to help treat acne by multiple mechanisms, including bacterial inhibition, had substantially lower, but measurable, activity, compared to true antibiotics. Their potency, generally ranging from 2000–64,000 µg/mL, was approximately 1000-fold less active than the designated antibiotics. However, their activity was maintained against all of the resistant bacteria tested, including highly resistant strains of S. aureus, S. epidermidis, and S. pneumoniae where almost all the antibiotics failed.

Previous reports of the direct antimicrobial activity of salicylic acid are limited, with disc diffusion measurements of activity in 1962 versus E. coli, Aerobacter aerogenes, Leuconostoc mesenteroides P-60, S. aureus, 'Streptococcus faecalis' [sic] and five fungi. In 2014 the MIC and Minimum Bactericidal Concentration (MBC) of salicylic acid and other phytochemicals were assessed against E. coli (MIC = 3200 µg/mL) and S. aureus (MIC = 1600 µg/mL), compared to MIC = 16000 µg/mL and 32000–64000 µg/mL, respectively in this study. A 2007 study showed 5 mM salicylate (approx. 700 µg/mL) halted growth of SH1100 S. aureus after 5h, though the same concentration only slightly slowed the growth of E. coli GC4468. A 2011 article on new antimicrobial formulations compared their activity against P. acnes to salicylic acid, with MIC50 for salicylic acid of 1000 µg/mL, compared to 8000 µg/mL in this study. A review of the effects of salicylate on bacteria was published in 2000, which summarized research showing that, at concentrations that do not substantially affect bacterial growth, salicylate can: (a) induce antibiotic resistance, (b) reduce resistance to some antibiotics; and (c) affect production of bacterial virulence factors. More recent studies have supported the reduction in susceptibility of organisms such as S. aureus or Salmonella enterica serovar Typhimurium to common antibiotics or antiseptics in the presence of salicylate. Further studies are warranted to see if topical use of salicylate for acne reduces the effectiveness of topical acne antibiotics.

The antimicrobial potential of azelaic acid has been more thoroughly studied than that of salicylic acid, with a review in 1993. The first observation that it exerted a bacteriostatic effect on aerobic and anaerobic bacteria (including Propionibacterium) appeared as a comment in a 1983 clinical report. A clinical trial noted a 224-fold lower activity of azelaic acid, nitrofurazone, silver sulphadiazine and mupirocin against MRSA, with MIC50 and MIC90 of azelaic acid, measured by agar dilution, were 850 µg/mL and 1150 µg/mL respectively. In 1991 concentrations of 500 mM (≈94,000 µg/mL) were reported to exert bactericidal activity against P. acnes in vitro at pH 6.0, with activity enhanced by lowering the pH to 5.6 but little activity at pH 7.0. A 1992 report compared the in vitro activities of the top antimicrobials azelaic acid, nitrofurazone, silver sulphadiazine and mupirocin against MRSA, with MIC50 and MIC90 of azelaic acid, measured by agar dilution, were 850 µg/mL and 1150 µg/mL respectively. Azelaic acid was slowly bactericidal at 2500 µg/mL, with around 3-log reduction from a starting inoculum of 10^6 CFU after 24 h; a resistance mutation rate of <1 x 10^-8 was observed. The authors of the 1993 review also noted in the review that they had conducted an in vitro experiment to assess the development of resistance in P. acnes or S. epidermidis over 53 days exposed to 2–4 mM (400–800 µg/mL) azelaic acid, with no changes in MIC detected.

Finally, benzoyl peroxide has long been known to have antimicrobial properties, with speculation of anti-septic action in the 1920s and treatment of acne/skin lesions in the 1930s. The history of its application for the treatment of acne was reviewed in 1987 and 2009. Survival curves of S. epidermidis, S. capitis, S. hominis, P. acnes, P. granulosum, P. avidum and P. ovale have been measured in the presence of 10^-2 – 10^-4 w/w benzoyl peroxide, with bacteria showing varying sensitivity but all killed at the higher concentrations. Another study looked at 10 sensitive and 10 erythromycin resistant strains of P. acnes, P. granulosum, P. avidum, and 10 sensitive and 10 erythromycin resistant strains of S. epidermidis, with benzoyl peroxide agar dilution MIC of 64–128 µg/mL and 512 µg/mL respectively (compared to BMD MIC of 2048 µg/mL in this study; their benzoyl peroxide parent solution had 5% w/w benzoyl peroxide but also contained carbomer 940, 14% alcohol, sodium hydroxide, dioctylsodium sulphosuccinate and fragrance). In 1989 MICs against nine P. acnes strains were reported to be between 100–800 µg/mL using a modified broth with added 2% Tween and glycerol to improve benzoyl peroxide activity.
Clindamycin, erythromycin and tetracycline topical treatments are generally in the 1–4% range, with dapsone for acne treatments: 2% is the maximum strength allowed in over-the-counter acne products in the United States). (NARSA) (see Table 5).

American Type Culture Collection (ATCC) or Network on Antimicrobial Resistance in Table 4.

| Compound Name       | Supplier/Batch          | MW       | Solvent       | Stock Solution Concentration (mg/mL) | Concentration range tested (µg/mL) |
|---------------------|-------------------------|----------|---------------|--------------------------------------|-----------------------------------|
| Azelaic acid        | Alfa Aesar Cat# 36308   | 188.22   | 100% DMSO     | 640                                  | 32,000–15                        |
|                     | Batch 5002P21N1         |          |               |                                      |                                   |
| Benzoyl peroxide 75%| Sigma Cat# 517909–5 G   | 242.22   | 100% DMSO     | 40.97                                | 2,048–1                           |
|                     | Batch mkbr5398v         |          |               |                                      |                                   |
| Clindamycin hydrochloride | Sigma Cat# PFI1159-1G  | 424.98   | H₂O           | 3.21                                 | 32–0.015                          |
|                     | Batch P500159           |          |               |                                      |                                   |
| Colistin sulfate    | Sigma Cat# C4461        | 1155.4   | H₂O           | 1.28                                 | 64–0.03                           |
|                     | Batch 018K1151          |          |               |                                      |                                   |
| Dapsone             | Sigma Cat# 46158-250mg  | 248.3    | 100% DMSO     | 82                                   | 4,100–2                          |
|                     | Batch SZBC072XV         |          |               |                                      |                                   |
| Erythromycin        | Sigma Cat# E5389-5G     | 733.93   | 20% DMSO      | 3.20                                 | 32–0.015                          |
|                     | Batch 011M1510V         |          |               |                                      |                                   |
| Oxacillin sodium salt hydrate | Sigma Cat# O1002-1G    | 401.43   | H₂O           | 3.20                                 | 64–0.03                           |
|                     | Batch 018K0610          |          |               |                                      |                                   |
| Salicylic acid      | Sigma Cat# A5376-100G   | 138.12   | 100% DMSO     | 640                                  | 32,000–15                        |
|                     |                        |          |               |                                      |                                   |
| Tetracycline hydrochloride | Sigma Cat#T7660-5G Batch PDS-064-048 | 480.90   | H₂O           | 3.20                                 | 32–0.015                          |
|                     |                        |          |               |                                      |                                   |
| Vancomycin          | Sigma Cat# 861987       | 1485.71  | H₂O           | 1.28                                 | 64–0.03                           |
|                     | Batch 085K0694          |          |               |                                      |                                   |

Table 4. Compounds assayed. *poor solubility at >512 µg/mL.

In summary, this study clearly demonstrates that acne agents used primarily for their skin exfoliating properties do indeed have modest, but widespread, antimicrobial activity against a range of skin-associated bacteria, at least when tested in broth microdilution assays. Many skin-related bacteria can form biofilms, which are notoriously more resistant to antimicrobial therapies than vegetative bacteria. The exfoliant topical agents are generally applied at concentrations up to 20-fold higher than topical antibiotics (though in some cases at equivalent concentrations), so they are likely to exert substantial antimicrobial effects despite their reduced antimicrobial potency. Benzoyl peroxide is used as 2.5–10% solutions in gel, cream, lotions or liquid, and salicylic acid as 15–20% concentrations, depending on solubility and expected activity range, as presented in Table 4.

Methods

Compound preparation. Stock solutions of compounds were prepared in different solvents at different concentrations, depending on solubility and expected activity range, as presented in Table 4.

Minimum Inhibitory Concentration (MIC) determinations. Bacterial strains were purchased from the American Type Culture Collection (ATCC) or Network on Antimicrobial Resistance in Staphylococcus aureus (NARS) (see Table 5).

Standard aerobic MIC Assay. The compounds along with standard antibiotics were serially diluted with Mueller Hinton broth (MHB) (Bacto laboratories, Cat. No 211443) two-fold across the wells of 96-well standard Polystyrene plates (Corning 3370). For antibiotics not initially dissolved in water, the highest solvent (DMSO) concentration in the final assay solution was 2%. Solvent controls have shown that this concentration does not interfere with bacteria growth. All bacteria strains were cultured in MHB at 37 °C overnight. A sample of each culture was then diluted 40-fold in fresh MHB and incubated at 37 °C for a further 2–3 h. The resultant mid-log phase cultures were diluted in MHB and added to each well of the compound-containing 96-well plates to give a final cell density of 5 × 10⁵ CFU/mL. All the plates were covered and incubated at 37 °C for 24 h. MICs were determined as the lowest concentration showing no visible growth by eye. Assays were conducted in duplicate, with two independent assays (n = 4).
Standard anaerobic MIC Assay. The MIC assay for anaerobic growth conditions was performed to the same procedure as the standard aerobic MIC assay described above with the following exceptions:

All steps were performed in a COY type B anaerobic chamber with the anaerobic atmosphere controlled by the introduction of 10%CO₂/5% H₂ in N₂, gas mix, catalyst Stak-Pak and O₂-H₂ gas analyzer, with H₂ levels kept at ~2% for the duration of the assay. Brain Heart Infusion (BHI) (OXOID CM1135B) media with 1% cysteine to further promote an anaerobic environment was used in replacement of MHB, and this broth was incubated in the anaerobic chamber for 24 h prior to use to allow sufficient atmosphere exchange. All the plates were covered and incubated at 37 °C for 48 h. MICs were determined as the lowest concentration showing no visible growth by eye.

### Table 5. Bacterial strains assayed.

| Species                                           | Strain                  | Strain designation                                                                 |
|---------------------------------------------------|-------------------------|-------------------------------------------------------------------------------------|
| Acinetobacter johnsonii                           | ATCC 17909              | Bouvet and Grimont NCTC10308 Type strain, isolated from duodenum                   |
| Bacillus cereus                                   | ATCC 11778              | Frankland and Frankland FDA strain PCI 213                                         |
| Bacillus megaterium                              | ATCC 13632              | De Bary KM                                                                         |
| Bacillus subtilis                                 | ATCC 6633               | subsp. spizizenii Nakamura et al. NRS 231                                           |
| Enterococcus faecium                              | ATCC 35667              | (Orla-Jensen) Schleifer and Kilpper-Balz LRA 55 03 77 quality control strain       |
| Enterococcus faecalis                            | ATCC 29212              | (Andrewes and Horder) Schleifer and Kilpper-Balz isolated from urine                |
| Escherichia coli                                  | ATCC 25922              | (Migula) Castellani and Chalmers FDA strain Seattle 1946                           |
| Micrococcus luteus                                | ATCC 4698               | (Schroeter) Cohn Type strain                                                        |
| Kocuria rosea (formerly Micrococcus roseus)       | ATCC 31251              | (Flugge) Stackebrandt et al. M-1054-1                                              |
| Catibacterium acnes (formerly Propionibacterium acnes) | ATCC 6919               | Scholz and Kilian NCTC 737 Type strain isolated from facial acne                    |
| Acidipropionibacterium acidipropionici (formerly Propionibacterium acidipropionici) | ATCC 25562 | VPI 0399 [14 x ] Type strain                                                        |
| Catibacterium granulosum (formerly Propionibacterium granulosum) | ATCC 25564 | Scholz and Kilian VPI 0507 Type strain                                              |
| Staphyloccocus aureus                             | ATCC 25923              | subsp. aureus Rosenbach Seattle 1945, MSSA                                          |
| Staphyloccocus aureus                             | ATCC 29213              | subsp. aureus Rosenbach Wichita, MSSA, isolated from wound                          |
| Staphyloccocus aureus                             | ATCC 43300              | subsp. aureus Rosenbach F-182, MRSA                                                |
| Staphyloccocus aureus                             | ATCC 33591              | subsp. aureus Rosenbach 328, MRSA                                                  |
| Staphyloccocus aureus                             | NRSI (ATCC 700699)      | subsp. aureus Rosenbach Mu50, VISA/MRSA                                             |
| Staphyloccocus aureus                             | VRSI (NR-46410)         | VRSA                                                                                 |
| Staphyloccocus capitis                            | ATCC 27840              | subsp. capitis Kloos and Schleifer, LK 499 Type strain                              |
| Staphyloccocus epidermidis                        | ATCC 14990              | (Winslow and Winslow) Evans Fussel [NCTC 11047] Type strain                         |
| Staphyloccocus epidermidis                        | ATCC 12228              | (Winslow and Winslow) Evans FDA strain PCI 1200                                     |
| Staphyloccocus epidermidis                        | NRS60 (NR-45891)        | VISE                                                                                 |
| Staphyloccocus warneri                            | ATCC 27836              | Kloos and Schleifer AW 25 Type strain, isolated from human skin                     |
| Streptococcus pneumoniae                         | ATCC 33400              | (Klein) Chester NCTC 7465 Type strain                                              |
| Streptococcus pneumoniae                         | ATCC 700677             | (Klein) Chester Slovakia 14-10 MDR Resistant to erythromycin, penicillin, and tetracycline, Sensitive to rifampin rifampicin and rifamycin AMP |
| Streptococcus pyogenes                            | ATCC 14289              | Rosenbach C203 S clinical isolate                                                  |
References

1. Williams, H. C., Dellavalle, R. P. & Garner, S. Acne vulgaris. Lancet 379, 361–372 (2012).
2. Hay, R. J. et al. The global burden of skin disease in 2010: an analysis of the prevalence and impact of skin conditions. J. Invest. Dermatol. 134, 1527–1534 (2014).
3. Alexeyev, O. A. et al. Why we continue to use the name Propionibacterium acnes. Brit. J. Dermatol. 179, 1227–1227 (2018).
4. Leyden, J. J. New understandings of the pathogenesis of acne. J. Am. Acad. Dermatol. 32, S15–S25 (1995).
5. Dawson, A. L. & Dellavalle, R. P. Acne vulgaris. BMJ 346, 2634 (2013).
6. Millikan, L. E. Acne therapy: old wine in new vessels – the promise (and pitfalls) of new drug deliveries and regimens. Exp. Rev. Dermatol. 4, 191–194 (2009).
7. Zaenglein, A. L. et al. Guidelines of care for the management of acne vulgaris. J. Am. Acad. Dermatol. 74, 945–973 (2016).
8. Adler, B. L., Kornmehl, H. & Armstrong, A. W. Antibiotic resistance in acne treatment. J. Am. Acad. Dermatol. 153, 810–811 (2017).
9. Nast, A. et al. European evidence-based (53) guideline for the treatment of acne – update 2016 – short version. J. Eur. Acad. Dermatol. Venereol. 30, 1261–1266 (2016).
10. Grice, E. A. et al. Topographical and Temporal Diversity of the Human Skin Microbiome. Science 324, 1190–1192 (2009).
11. Brandwein, M., Steinberg, D. & Mesher, S. Microbial biofilms and the human skin microbiome. npg Biofilms and Microbicides 2, 3 (2016).
12. Ross, A. A., Müller, K. M., Weese, J. S. & Neufeld, J. D. Comprehensive skin microbiome analysis reveals the uniqueness of human skin and evidence for phylosymbiosis within the class. Mammalia. Proc. Nat. Acad. Sci. 115, E5786–E5798 (2018).
13. Byrd, A. L., Belkaid, Y. & Segre, J. A. The human skin microbiome. Nature Rev. Microbiol. 16, 143–155 (2018).
14. Meisel, J. S. et al. Skin microbiome surveys are strongly influenced by experimental design. J. Invest. Dermatol. 136, 947–956 (2016).
15. Oh, J., Byrd, A. L., Park, M., Kong, H. H. & Segre, J. A. Temporal Stability of the Human Skin Microbiome. Cell 165, 854–866 (2016).
16. Oh, J. et al. Biogeography and individuality shape function in the human skin metagenome. Nature 514, 59–64 (2014).
17. Schloss, P. D. An integrated view of the skin microbiome. Nature 514, 44–45 (2014).

Scientific Reports | (2019) 9:14658 | https://doi.org/10.1038/s41598-019-50746-4

Acknowledgements

This research was supported financially by funding from Mimetica Pty Ltd. MATB, AGE and SR, and AK were supported in part by Wellcome Trust Seeding Drug Discovery Award (094977/Z/10/Z) and Wellcome Trust Strategic Award 104797/Z/14/Z. MAC is a former NHMRC Australian Fellow (AF511105) and current NHMRC Principal Research Fellow (APP1059354) who holds a fractional Professorial Research Fellow appointment at...
the University of Queensland with his remaining time as CEO of Inflazome Ltd, a company headquartered in Dublin, Ireland that is developing drugs to address clinical unmet needs in inflammatory disease by targeting the inflammasome. Strains *S. epidermidis* Strain NR-45891 (NRS60) and *S. aureus* NR-46410 (VRS1) were provided by the Network on Antimicrobial Resistance in *Staphylococcus aureus* (NARSA) for distribution by BEI Resources, NIAID, NIH. *S. aureus* NRS1 (Mu50, ATCC 700699) was originally provided by NARSA, now available from American Type Culture Collection (ATCC), all other ATCC strains were acquired directly from ATCC.

**Author Contributions**

M.A.T.B. conceptualized the study, acquired specific funding for the project, and wrote the original draft of the manuscript, with all authors contributing to manuscript review and editing. A.G.E., A.M.K. and S.R. conducted the investigations and analysis, with A.G.E. providing project administration. M.A.C. acquired general support funding and provided supervision.

**Additional Information**

**Competing Interests:** The authors declare no competing interests.

**Publisher’s note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit [http://creativecommons.org/licenses/by/4.0/](http://creativecommons.org/licenses/by/4.0/).